R 0001/19 (Fundamental violation of the right to be heard) of 17.10.2019
- European Case Law Identifier
- ECLI:EP:BA:2019:R000119.20191017
- Date of decision
- 17 October 2019
- Case number
- R 0001/19
- Petition for review of
- T 2471/16 2018-05-23
- Application number
- 11196067.0
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen and members (B)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Pharmaceutical composition for dermal use comprising calcipotriol and betamethasone for treating psoriasis
- Applicant name
- Leo Pharma A/S
- Opponent name
- Teva Pharmaceutical Industries Ltd.
PENTAFARMA S.A.
Generics [UK] Limited (trading as Mylan)
Sandoz B.V. - Board
- -
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 112a(2)(c)European Patent Convention Art 113(1)
- Keywords
- Petition admissible (yes) - obligation to raise objection (no)
Right to be heard - violation (no)
no obligation for a Board to inform a party that it deems a particular argument relevant - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The petition for review is unanimously rejected as being clearly unallowable.